Results 71 to 80 of about 170,034 (262)

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

A Membrane Transporter Determines the Spectrum of Activity of a Potent DNA-Targeted Hybrid Anticancer Agent [PDF]

, 2020
Cytotoxic drugs that are mechanistically distinct from current chemotherapies are attractive components of personalized combination regimens for combating aggressive forms of cancer. To gain insight into the cellular mechanism of a highly potent platinum–
Noah, Watkins, Xiyuan, Yao, Heather, Brown-Harding, Ulrich, Bierbach   +3 more
core   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

ZnO Nanoparticles: A Promising Anticancer Agent [PDF]

, 2016
Nanoparticles, with their selective targeting capabilities and superior efficacy, are becoming increasingly important in modern cancer therapy and starting to overshadow traditional cancer therapies such as chemotherapy, radiation and surgery.
Gunjan Bisht, Bisht, Gunjan, Sagar Rayamajhi, Rayamajhi, Sagar   +3 more
core   +2 more sources

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Synergistic Effect of Retinoic Acid Polymeric Micelles and Prodrug for the Pharmacodynamic Evaluation of Tumor Suppression

Frontiers in Pharmacology, 2019
All-trans retinoic acid (ATRA) is an effective agent that induces differentiation, inhibits cell proliferation, and acts as an anticancer agent. ATRA was successfully conjugated with Pluronic F127 via esterification to enhance its anticancer effects ...
Yan-Hua Zhu, Ning Ye, Xin-Feng Tang, Malik Ihsanullah Khan, Hong-Liang Liu, Ning Shi, Li-Feng Hang   +6 more
doaj   +1 more source

Structure and Absolute Stereochemistry of the Anticancer Agent EBC-23 from the Australian Rainforest [PDF]

, 2016
Structure and Absolute Stereochemistry of the Anticancer Agent EBC-23 from the Australian ...
Victoria A. Gordon (637472), Rebecca L. Grange (2261413), Paul Reddell (2408398), Craig M. Williams (1939036), Jenny Johns (2408404), Peter G. Parsons (251832), Lin Dong (1458793), Achim Porzelle (2308447), Heiko Schill (2408401)   +8 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Benzothiazole derivatives as anticancer agents

Journal of Enzyme Inhibition and Medicinal Chemistry, 2020
Benzothiazole (BTA) belongs to the heterocyclic class of bicyclic compounds. BTA derivatives possesses broad spectrum biological activities such as anticancer, antioxidant, anti-inflammatory, anti-tumour, antiviral, antibacterial, anti-proliferative ...
Ali Irfan, Fozia Batool, Syeda Andleeb Zahra Naqvi, Amjad Islam, Sameh M. Osman, Alessio Nocentini, Siham A. Alissa, Claudiu T. Supuran   +7 more
doaj   +1 more source

Kinetic modelling of the role of the aldehyde dehydrogenase enzyme and the breast cancer resistance protein in drug resistance and transport [PDF]

, 2011
A compartmental model for the in vitro uptake kinetics of the anti-cancer agent topotecan (TPT) has been extended from a previously published model. The extended model describes the drug activity and delivery of the pharmacologically active form to the ...
N.D. Evans, Evans, Neil D., M.J. Chappell, Errington, Rachel J., R.J. Errington, Smith, Paul J., Smith, Paul James, Atari, M. I., Chappell, M. J., P.J. Smith, Chappell, M. J. (Michael J.), M.I. Atari, Errington, Rachel Jane, Evans, N. D.   +13 more
core   +1 more source